Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma
August 24, 2021 07:00 AM Eastern Daylight Time Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical…
Blog - Melanoma360
08/25/2021
Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma
August 24, 2021 07:00 AM Eastern Daylight Time Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical…
|
|
07/29/2021
In Plain English—June 2021 News from ASCO, the American Society of Clinical Oncology
By Kim Margolin, M.D. You might have seen the term ASCO as you’ve scrolled through melanoma websites or research documents…
|
07/23/2021
President’s Letter | July 2021
From the Desk of Samantha Guild I was struck several times this month with the idea that the fight against…
|
07/22/2021
FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin
July 21, 2021 (repost) Sara Karlovitch The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for…
|
|
07/21/2021
Chad Freitas and the Skiff Sailing Foundation
By Alicia Rowell, Vice President It was 1986. Chad Freitas was six years old, and he and his dad drove…
|
07/15/2021
The Psychological Well-Being of Skin Cancer Patients
By Alicia Rowell, Vice President With a mom who is a professor of Research Methods in Applied Psychology at the…
07/15/2021
International Survivor Spotlight: Hedva Gonen, Israel
By Mara Klecker Hedva Gonen received her diagnosis via email while sitting alone in her home in Haifa, Israel. As…
|
|
07/12/2021
Gut Microbes Signal Response to Immune Therapy in Melanoma
(re-post from original article in GEN News) Programmed cell death protein 1 (PD-1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) are…
|
|
06/30/2021
EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients
Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage II melanoma patients EUROPEAN ORGANISATION…
|
|
06/15/2021
Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma
June 14, 2021 08:03 AM Eastern Daylight Time | Source: Business Wire DURHAM, N.C.–(BUSINESS WIRE)–Istari Oncology, Inc., a clinical-stage biotechnology…
|
|
Recent Posts
Dec. 12, 2024
Navigating Melanoma Together: 2024 Podcast Wrap-Up
Dec. 10, 2024
Beyond the Clinic’s New Host: Introducing Dr. Sam Siegel
Dec. 09, 2024
Managing Melanoma During the Holiday Season
Dec. 05, 2024
Beyond the Clinic’s New Host: Dr. Sam Siegel Brings a Fresh Voice to Survivorship
Dec. 03, 2024